PharmaCell to Finalize Purchase of Cell Therapy Production Facility

04-Jun-2014 - Netherlands

PharmaCell B.V. announced that it finalized its purchase of the state-of-the-art cell therapy production facility fromTiGenix NV. TiGenix, a leading European cell therapy company has been producing its marketed product for cartilage repair, ChondroCelect® at the site in Sittard-Geleen, close to Maastricht (The Netherlands), since the beginning of 2013.

Following the acquisition, PharmaCell will continue to operate its Maastricht facility in addition to the site at Sittard-Geleen. The Maastricht facility offers non-GMP process development and flexible GMP-production facilities for early- to mid-stage clinical trials in cell therapy. The Cell Manufacturing Facility Geleen will offer clients the opportunity to support late stage clinical trials and commercial production for the industry. Taken together, PharmaCell offers a comprehensive contract manufacturing service package for cell therapy companies along the development pathway from translational work all the way to the commercial stage. With both TiGenix (ChondroCelect®) and Dendreon Corporation (for Provenge®) as partners, the company has two commercial cell therapy products under contract. In addition, work is ongoing on early stage clinical trials and translational projects.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances